Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
about
A focused review of the pathogenesis, diagnosis, and management of tumor lysis syndrome for the interventional radiologistRasburicase in the management of tumor lysis: an evidence-based review of its place in therapyTumor lysis syndrome: new challenges and recent advances.Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma.Burkitt lymphoma involving jejunum in children.Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group ReportA pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).Intensive care of the cancer patient: recent achievements and remaining challengesTumor lysis syndrome in the emergency department: challenges and solutions.Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy.Tumor Lysis Syndrome in Patients with Hematological Malignancies.Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.Evaluation and characterization of tumor lysis syndrome before and after chemotherapy among pediatric oncology patients in Tikur Anbessa specialized hospital, Addis Ababa, EthiopiaNot the Typical Pneumonia: An Unusual Case of Rasburicase-induced Methomoglobinemia
P2860
Q27012513-ED34F7BF-92ED-48DF-8635-607D18CBE3BDQ28082089-FF50172B-EAE0-4163-89CE-B1911B3EB1DBQ33595615-1998214B-7C85-4166-837F-5345468E6643Q33719237-8131406B-A72E-43CD-B702-8D395FBD9CB4Q34829173-F6628175-CD27-4168-9738-98AB73497013Q35683889-1E5385B8-3AFD-46A6-A093-57AAAC7DEAB6Q37329442-24863A1F-917C-4451-876C-112324874EC7Q37354482-B8B5885D-F134-4B8D-8242-E71FEAD3C4EBQ37586944-157A745F-6868-4D99-BD40-D1BDD879F702Q37929882-FCC74F84-DA49-489D-90C7-AB48CC1F3270Q38826321-120291C9-0C35-45D7-8F1C-0D3D5EF0778BQ41684763-07E8B924-3730-425D-81AD-DA97B6CDE363Q46949121-5D8AFBA2-2506-4E16-B35E-0064953C271EQ47135590-4E8D5FCA-845E-479D-958A-00BB07E9E845Q48375750-7F0A2104-90CB-420D-BA00-1CF4AD3F44FBQ56515774-5CAC2DCA-1D6A-4890-902A-A1AC2A471712Q57495783-F9C76100-3041-425E-A091-707F3DC505F1
P2860
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@ast
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@en
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@nl
type
label
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@ast
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@en
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@nl
prefLabel
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@ast
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@en
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@nl
P2093
P1433
P1476
Incidence of tumor lysis syndr ...... hylactic use of urate oxidase.
@en
P2093
P304
P356
10.1007/S00277-003-0608-2
P577
2003-02-19T00:00:00Z